Molecular Targets of Heterocyclic Compounds for Cancer Therapy: A Comprehensive Review

Edited by Vivek Asati PhD and Ankur Vaidya PhD, this book provides an in-depth exploration of recently developed treatments for cancer therapy, focusing on molecular targets that are genetically altered in cancer cells and essential for tumor development and survival.

The Rise of Targeted Drugs in Cancer Treatment

Considerable research effort has been devoted to the development of targeted drugs that inhibit the action of pathogenic kinases. Clinical studies have validated the positive effects of kinase inhibitors for cancer treatment, offering new hope for patients and researchers alike.

Molecular Targets for Cancer Therapy: An Expert Guide

This book delves into a range of molecular targets, including ALK2, ATR, CK, Src-Abl, EGFR, Fyn-Blk-Lyn, IGFs, and PAK1. Each chapter is written by experts who actively work on these targets, providing readers with a comprehensive understanding of how they can be utilized for novel cancer therapies.

A Valuable Resource for Cancer Researchers and Oncologists

This comprehensive compilation is an essential resource for cancer researchers, oncologists, graduate students, and members of the biomedical field interested in the potential of novel cancer therapies based on molecular targets.

Key features of this book include:

• Discussions on recently discovered molecular targets for cancer therapy
• Updated literature on heterocyclic compounds, a crucial construction motif for the development of new anticancer drugs
• A comprehensive compilation of recently introduced anticancer drugs in the market, including their health outcomes and pharmacoeconomics

Published by Academic Press, this 502-page paperback book is set to be released on May 3, 2024. With its focus on molecular targets and comprehensive reviews, this book is poised to become a valuable resource in the fight against cancer.